ELAN: CFO awarded 109,857 RSUs and 53,869 options on 10/01/2025

Rhea-AI Filing Summary

Elanco Animal Health Inc. (ELAN) reported insider awards to Executive Vice President and Chief Financial Officer Robert M. VanHimbergen. The Form 4 discloses a grant of 109,857 restricted stock units that vest in three equal tranches on July 7, 2026, July 7, 2027, and July 7, 2028. The filing also shows a grant of 53,869 employee stock options with an exercise price of $20.80, exercisable beginning in the same three-tranche schedule and expiring on October 1, 2035. Both holdings are reported as direct ownership following the transactions. The Form 4 was signed by an attorney-in-fact on behalf of Mr. VanHimbergen and lists the transaction date as October 1, 2025.

Positive

• 109,857 restricted stock units granted to the EVP & CFO with multi-year vesting
• 53,869 stock options granted with an exercise price of $20.80 and expiration on 10/01/2035
• Vesting schedule aligns executive incentives with long-term performance: 7/7/2026, 7/7/2027, 7/7/2028

Negative

• None.

Insights

Corporate Compensation Specialist

Senior finance officer received multi-year equity awards tied to future vesting dates.

The filing shows a grant of 109,857 restricted stock units and 53,869 stock options to the company's EVP & CFO, indicating long-term retention incentives. These awards vest in three equal tranches on July 7, 2026, July 7, 2027, and July 7, 2028, aligning the executive's compensation with multi-year performance or tenure goals.

This structure typically aims to retain key management and align interests with shareholders over the vesting period; the disclosed $20.80 exercise price and October 1, 2035 expiration set the economic terms for the options.

Equity Dilution Analyst

Equity awards increase outstanding potential shares but are standard executive grants.

The reported 109,857 RSUs convert to common shares upon vesting and the 53,869 options represent potential share issuance if exercised before October 1, 2035. Both are reported as direct holdings after the grants.

Investors should note these are standard compensation instruments; the Form 4 does not disclose any exercised options or changes to outstanding share counts beyond the awards themselves.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VanHimbergen Robert M

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CFO

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		A		109,857(1)	A	$0	109,857	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$20.8	10/01/2025		A		53,869		(2)	10/01/2035	Common Stock	53,869	$0	53,869	D

Explanation of Responses:

1. Grant of restricted stock units vesting as follows: one-third vesting on July 7, 2026, one-third vesting on July 7, 2027, and the remaining vesting on July 7, 2028.

2. Grant of stock options vesting as follows: one-third vesting on July 7, 2026, one-third vesting on July 7, 2027, and the remaining vesting on July 7, 2028.

	/s/ Amy C. Seidel, Attorney-in-Fact for Robert M. VanHimbergen	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Elanco (ELAN) disclose in this Form 4?

The filing reports grants to EVP & CFO Robert M. VanHimbergen of 109,857 restricted stock units and 53,869 stock options on 10/01/2025.

When do the restricted stock units and options vest for ELAN insider grants?

Both the RSUs and the stock options vest in three equal tranches on July 7, 2026, July 7, 2027, and July 7, 2028.

What is the exercise price and expiration for the stock options granted to the ELAN CFO?

The options have an exercise price of $20.80 and an expiration date of October 1, 2035.

Are the awarded securities reported as direct or indirect ownership?

The Form 4 reports both the restricted stock units and the options as direct ownership following the grants.

Who signed the Form 4 for the ELAN reporting person?

The Form 4 was signed by Amy C. Seidel, Attorney-in-Fact for Robert M. VanHimbergen, on 10/03/2025.